Declarations:
Consent for publication: Written informed consent was obtained
from the patient for publication of this case report and the
accompanying image. A copy of the written consent is available for
review by the Editor-in-Chief of this journal on request.
Availability of data and materials: The datasets used and/or analyzed
during the current study are available from the corresponding author on
reasonable request.
Competing interests: None to be declared.
Funding statement: This article did not receive any specific
grant from funding agencies in the public, commercial, or not-for-profit
sectors.
Author contribution statement: Almurtada Razok and Abdullah
Shams performed literature review and wrote the original draft of the
manuscript. Ahmed Almeer and Muhammad Zahid supervised the writing
process and revised the manuscript. All authors approved the final
version for submission.
Acknowledgements: Open access funding was provided by Qatar
National Library (QNL).
References :
[1] Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence
of Guillain-Barré syndrome: a systematic review and
meta-analysis. Neuroepidemiology . 2011;36(2):123-133.
doi:10.1159/000324710
[2] Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré
syndrome. Lancet . 2016;388(10045):717-727.
doi:10.1016/S0140-6736(16)00339-1
[3] Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine
phase 3 trials. Nat Med . 2021;27(2):205-211.
doi:10.1038/s41591-021-01230-y
[4] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart
S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19
Vaccine. N Engl J Med . 2020;383(27):2603-2615.
doi:10.1056/NEJMoa2034577
[5] Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA,
Ziegler DW, Retailliau HF, et al. Guillain-Barre syndrome following
vaccination in the National Influenza Immunization Program, United
States, 1976–1977. Am J Epidemiol . 1979;110(2):105-123.
doi:10.1093/oxfordjournals.aje.a112795
[6]. Walling AD, Dickson G. Guillain-Barré syndrome. Am Fam
Physician . 2013;87(3):191-197.
[7]. Alshekhlee A, Hussain Z, Sultan B, Katirji B. Guillain-Barré
syndrome: incidence and mortality rates in US
hospitals. Neurology . 2008;70(18):1608-1613.
doi:10.1212/01.wnl.0000310983.38724.d4
[8]. Bogliun G, Beghi E; Italian GBS Registry Study Group. Incidence
and clinical features of acute inflammatory polyradiculoneuropathy in
Lombardy, Italy, 1996. Acta Neurol Scand . 2004;110(2):100-106.
doi:10.1111/j.1600-0404.2004.00272.x
[9]. van Doorn PA, Ruts L, Jacobs BC. Clinical features,
pathogenesis, and treatment of Guillain-Barré syndrome. Lancet
Neurol . 2008;7(10):939-950. doi:10.1016/S1474-4422(08)70215-1
[10]. Hughes RA, Cornblath DR. Guillain-Barré
syndrome. Lancet . 2005;366(9497):1653-1666.
doi:10.1016/S0140-6736(05)67665-9
[11]. Souayah N, Nasar A, Suri MF, Qureshi AI. Guillain-Barre
syndrome after vaccination in United States a report from the CDC/FDA
Vaccine Adverse Event Reporting System. Vaccine .
2007;25(29):5253-5255. doi:10.1016/j.vaccine.2007.03.053
[12]. Tuttle J, Chen RT, Rantala H, Cherry JD, Rhodes PH, Hadler S.
The risk of Guillain-Barré syndrome after tetanus-toxoid-containing
vaccines in adults and children in the United States. Am J Public
Health . 1997;87(12):2045-2048. doi:10.2105/ajph.87.12.2045
[13]. Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and
Guillain-Barré syndrome. Drug Saf . 2009;32(4):309-323.
doi:10.2165/00002018-200932040-00005
[14]. Waheed S, Bayas A, Hindi F, Rizvi Z, Espinosa PS. Neurological
Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer
COVID-19 Vaccine. Cureus . 2021;13(2):e13426. Published 2021 Feb
18. doi:10.7759/cureus.13426
Figures and captions :
Figure 1:
Magnetic resonance image of the spine with intravenous gadolinium
showing bilateral contrast enhancement of the nerve roots in the lumbar
region and the upper part of the cauda equina (as indicated by the
arrows).